MX9205568A - Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida. - Google Patents

Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.

Info

Publication number
MX9205568A
MX9205568A MX9205568A MX9205568A MX9205568A MX 9205568 A MX9205568 A MX 9205568A MX 9205568 A MX9205568 A MX 9205568A MX 9205568 A MX9205568 A MX 9205568A MX 9205568 A MX9205568 A MX 9205568A
Authority
MX
Mexico
Prior art keywords
ribofuranosil
1beta
carboxamide
imidazole
amino
Prior art date
Application number
MX9205568A
Other languages
English (en)
Inventor
Harry E Gruber
Kevin M Mullane
Paul Kevin Laikind
Original Assignee
Gensia Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gensia Pharma filed Critical Gensia Pharma
Publication of MX9205568A publication Critical patent/MX9205568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

Métodos para evitar el daño al tejido asociado con un flujo sanguíneo disminuido en un ser humano, mediante la administración de AICA ribósido, o un promedicamento del mismo, en una cantidad que da una concentración en el plasma sanguíneo de entre 1 mg/ml y 20 mg/ml de AICA ribósido durante el tiempo suficiente para reducir el riesgo del daño al tejido en el ser humano.
MX9205568A 1991-09-30 1992-09-30 Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida. MX9205568A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77002391A 1991-09-30 1991-09-30
US94910192A 1992-09-21 1992-09-21

Publications (1)

Publication Number Publication Date
MX9205568A true MX9205568A (es) 1994-03-31

Family

ID=27118261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9205568A MX9205568A (es) 1991-09-30 1992-09-30 Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.

Country Status (9)

Country Link
US (1) US5817640A (es)
EP (2) EP0560967A1 (es)
JP (1) JPH06503359A (es)
AU (2) AU2762792A (es)
CA (1) CA2096825A1 (es)
IL (1) IL103294A0 (es)
MX (1) MX9205568A (es)
NO (1) NO931886L (es)
WO (1) WO1993006833A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120340T1 (de) * 1991-10-31 1995-04-15 Unilever Nv Mit dem löffel essbare, nichtmilchhaltige saure sahne.
US6191136B1 (en) * 1997-11-07 2001-02-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
WO2001010449A1 (en) * 1999-08-09 2001-02-15 Trustees Of Boston University Method of maintaining vascular integrity using aicar (5-amino-4-imidazole riboside) and related compounds
AU2001268236A1 (en) * 2000-06-06 2001-12-17 Trustees Of Boston University Use of aicar and related compounds
US20030212034A1 (en) * 2001-06-11 2003-11-13 Winder William W Method of treatment of obesity and paralyzed muscle and ergogenic aids
ES2192495B1 (es) * 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
JP4754823B2 (ja) 2002-10-07 2011-08-24 ザイモジェネティクス， インコーポレイテッド Ｆｇｆ１８の投与方法
US20040199114A1 (en) * 2003-04-01 2004-10-07 Alsius Corporation Intravascular heat exchange catheter with tissue preservative
CA2602291C (en) 2005-03-28 2015-08-11 Pericor Therapeutics, Inc. Treatments for preventing or reducing adverse effects in a patient having decreased left ventricular function
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
WO2009093925A1 (en) * 2008-01-23 2009-07-30 United Technologies Ut Ag COSMETIC COMPOSITIONS COMPRISING 5-AMINO-L-β-D- RIBOFURANOSYL-LH-IMIDAZOLE-4-CARBOXAMIDE OR DERIVATIVES, OR SALTS THEREOF
EP2349284B1 (en) * 2008-10-03 2016-11-23 Pericor Therapeutics, Inc. Treatment of acute decompensated heart failure
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
US11834469B2 (en) 2018-08-06 2023-12-05 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
AU5668886A (en) * 1986-03-27 1987-10-20 Harry Edward Gruber A method of increasing adenosine excretion
US5118601A (en) * 1986-03-27 1992-06-02 The Regents Of The University Of California Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
EP0427799B1 (en) * 1989-01-24 1994-11-30 Gensia, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5187162A (en) * 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
IL99124A (en) * 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
IL108524A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs

Also Published As

Publication number Publication date
US5817640A (en) 1998-10-06
CA2096825A1 (en) 1993-03-31
NO931886L (no) 1993-07-27
IL103294A0 (en) 1993-05-13
JPH06503359A (ja) 1994-04-14
NO931886D0 (no) 1993-05-25
EP0535884A1 (en) 1993-04-07
AU4210696A (en) 1996-04-26
EP0560967A1 (en) 1993-09-22
AU2762792A (en) 1993-05-03
WO1993006833A1 (en) 1993-04-15

Similar Documents

Publication Publication Date Title
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
CR6458A (es) Composiciones de valdecoxib
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
AR035642A1 (es) Uso de una composicion de celecoxib para el alivio rapido del dolor
ES2087061T3 (es) Utilizacion de ribosido o ribotido de aica para la fabricacion de un medicamento contra la crisis cardiaca o el infarto de miocardio en los pacientes que sufren de ateroesclerosis.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
CO4700482A1 (es) Formulaciones de un analogo monomero de insulina
CO4970691A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
SE8402560L (sv) Farmaceutisk komposition
ATE50499T1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
CO4230093A1 (es) Derivados del indol y sus usos medicos
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
ES2142430T3 (es) Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral.
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
KR910005858A (ko) 지방산 요법
AU8687391A (en) Lithium treatment
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar